171 related articles for article (PubMed ID: 31638190)
1. The HSP90 inhibitor onalespib potentiates 177Lu‑DOTATATE therapy in neuroendocrine tumor cells.
Lundsten S; Spiegelberg D; Stenerlöw B; Nestor M
Int J Oncol; 2019 Dec; 55(6):1287-1295. PubMed ID: 31638190
[TBL] [Abstract][Full Text] [Related]
2. The HSP90 inhibitor Onalespib exerts synergistic anti-cancer effects when combined with radiotherapy: an in vitro and in vivo approach.
Spiegelberg D; Abramenkovs A; Mortensen ACL; Lundsten S; Nestor M; Stenerlöw B
Sci Rep; 2020 Apr; 10(1):5923. PubMed ID: 32246062
[TBL] [Abstract][Full Text] [Related]
3. The radiosensitizer Onalespib increases complete remission in
Lundsten S; Spiegelberg D; Raval NR; Nestor M
Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):980-990. PubMed ID: 31912256
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Onalespib, a Long-Acting Second-Generation HSP90 Inhibitor, as a Single Agent and in Combination with Temozolomide against Malignant Gliomas.
Canella A; Welker AM; Yoo JY; Xu J; Abas FS; Kesanakurti D; Nagarajan P; Beattie CE; Sulman EP; Liu J; Gumin J; Lang FF; Gurcan MN; Kaur B; Sampath D; Puduvalli VK
Clin Cancer Res; 2017 Oct; 23(20):6215-6226. PubMed ID: 28679777
[No Abstract] [Full Text] [Related]
5. Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour.
Wagner AJ; Agulnik M; Heinrich MC; Mahadevan D; Riedel RF; von Mehren M; Trent J; Demetri GD; Corless CL; Yule M; Lyons JF; Oganesian A; Keer H
Eur J Cancer; 2016 Jul; 61():94-101. PubMed ID: 27156227
[TBL] [Abstract][Full Text] [Related]
6. Heat shock protein 90 is a promising target for effective growth inhibition of gastrointestinal neuroendocrine tumors.
Gloesenkamp C; Nitzsche B; Lim AR; Normant E; Vosburgh E; Schrader M; Ocker M; Scherübl H; Höpfner M
Int J Oncol; 2012 May; 40(5):1659-67. PubMed ID: 22246317
[TBL] [Abstract][Full Text] [Related]
7. Emergence of resistance to tyrosine kinase inhibitors in non-small-cell lung cancer can be delayed by an upfront combination with the HSP90 inhibitor onalespib.
Courtin A; Smyth T; Hearn K; Saini HK; Thompson NT; Lyons JF; Wallis NG
Br J Cancer; 2016 Oct; 115(9):1069-1077. PubMed ID: 27673365
[TBL] [Abstract][Full Text] [Related]
8. 177Lu-octreotate therapy for neuroendocrine tumours is enhanced by Hsp90 inhibition.
Hofving T; Sandblom V; Arvidsson Y; Shubbar E; Altiparmak G; Swanpalmer J; Almobarak B; Elf AK; Johanson V; Elias E; Kristiansson E; Forssell-Aronsson E; Nilsson O
Endocr Relat Cancer; 2019 Apr; 26(4):437-449. PubMed ID: 30730850
[TBL] [Abstract][Full Text] [Related]
9. The novel HSP90 inhibitor AT13387 potentiates radiation effects in squamous cell carcinoma and adenocarcinoma cells.
Spiegelberg D; Dascalu A; Mortensen AC; Abramenkovs A; Kuku G; Nestor M; Stenerlöw B
Oncotarget; 2015 Nov; 6(34):35652-66. PubMed ID: 26452257
[TBL] [Abstract][Full Text] [Related]
10. Effects of novel somatostatin-dopamine chimeric drugs in 2D and 3D cell culture models of neuroendocrine tumors.
Herrera-Martínez AD; van den Dungen R; Dogan-Oruc F; van Koetsveld PM; Culler MD; de Herder WW; Luque RM; Feelders RA; Hofland LJ
Endocr Relat Cancer; 2019 Jun; 26(6):585-599. PubMed ID: 30939452
[TBL] [Abstract][Full Text] [Related]
11. Phase 1 study of the HSP90 inhibitor onalespib in combination with AT7519, a pan-CDK inhibitor, in patients with advanced solid tumors.
Do KT; O'Sullivan Coyne G; Hays JL; Supko JG; Liu SV; Beebe K; Neckers L; Trepel JB; Lee MJ; Smyth T; Gannon C; Hedglin J; Muzikansky A; Campos S; Lyons J; Ivy P; Doroshow JH; Chen AP; Shapiro GI
Cancer Chemother Pharmacol; 2020 Dec; 86(6):815-827. PubMed ID: 33095286
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387) administered on a daily for 2 consecutive days per week dosing schedule in patients with advanced solid tumors.
Do K; Speranza G; Chang LC; Polley EC; Bishop R; Zhu W; Trepel JB; Lee S; Lee MJ; Kinders RJ; Phillips L; Collins J; Lyons J; Jeong W; Antony R; Chen AP; Neckers L; Doroshow JH; Kummar S
Invest New Drugs; 2015 Aug; 33(4):921-30. PubMed ID: 26082332
[TBL] [Abstract][Full Text] [Related]
13. Molecular imaging of EGFR and CD44v6 for prediction and response monitoring of HSP90 inhibition in an in vivo squamous cell carcinoma model.
Spiegelberg D; Mortensen AC; Selvaraju RK; Eriksson O; Stenerlöw B; Nestor M
Eur J Nucl Med Mol Imaging; 2016 May; 43(5):974-982. PubMed ID: 26627081
[TBL] [Abstract][Full Text] [Related]
14. Disruption of DNA Repair and Survival Pathways through Heat Shock Protein Inhibition by Onalespib to Sensitize Malignant Gliomas to Chemoradiation Therapy.
Xu J; Wu PJ; Lai TH; Sharma P; Canella A; Welker AM; Beattie CE; Elder JB; Easley M; Lonser R; Jacob NK; Pietrzak M; Timmers CM; Lang F; Sampath D; Puduvalli VK
Clin Cancer Res; 2022 May; 28(9):1979-1990. PubMed ID: 35140124
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamic and Clinical Results from a Phase I/II Study of the HSP90 Inhibitor Onalespib in Combination with Abiraterone Acetate in Prostate Cancer.
Slovin S; Hussain S; Saad F; Garcia J; Picus J; Ferraldeschi R; Crespo M; Flohr P; Riisnaes R; Lin C; Keer H; Oganesian A; Workman P; de Bono J
Clin Cancer Res; 2019 Aug; 25(15):4624-4633. PubMed ID: 31113841
[TBL] [Abstract][Full Text] [Related]
16. Combination of 5-Fluorouracil with Epigenetic Modifiers Induces Radiosensitization, Somatostatin Receptor 2 Expression, and Radioligand Binding in Neuroendocrine Tumor Cells In Vitro.
Jin XF; Auernhammer CJ; Ilhan H; Lindner S; Nölting S; Maurer J; Spöttl G; Orth M
J Nucl Med; 2019 Sep; 60(9):1240-1246. PubMed ID: 30796167
[TBL] [Abstract][Full Text] [Related]
17. The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models.
Nölting S; Rentsch J; Freitag H; Detjen K; Briest F; Möbs M; Weissmann V; Siegmund B; Auernhammer CJ; Aristizabal Prada ET; Lauseker M; Grossman A; Exner S; Fischer C; Grötzinger C; Schrader J; Grabowski P;
PLoS One; 2017; 12(8):e0182852. PubMed ID: 28800359
[TBL] [Abstract][Full Text] [Related]
18.
Mohajershojai T; Jha P; Boström A; Frejd FY; Yazaki PJ; Nestor M
Front Oncol; 2022; 12():849338. PubMed ID: 35433442
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the Therapeutic Response to Treatment with a 177Lu-Labeled Somatostatin Receptor Agonist and Antagonist in Preclinical Models.
Dalm SU; Nonnekens J; Doeswijk GN; de Blois E; van Gent DC; Konijnenberg MW; de Jong M
J Nucl Med; 2016 Feb; 57(2):260-5. PubMed ID: 26514177
[TBL] [Abstract][Full Text] [Related]
20. HSP90 inhibition depletes DNA repair proteins to sensitize acute myelogenous leukemia to nucleoside analog chemotherapeutics.
Lai TH; Mitchell S; Wu PJ; Orwick S; Liu C; Ravikrishnan J; Woyach J; Mims A; Plunkett W; Puduvalli VK; Byrd JC; Lapalombella R; Sampath D
Leuk Lymphoma; 2019 Sep; 60(9):2308-2311. PubMed ID: 30773117
[No Abstract] [Full Text] [Related]
[Next] [New Search]